Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Adaptive Biotechnologies Corporation ADPT

Healthcare  —  Diagnostics & Research
29.43 (0.14) (0.47%) as of 25 Sep
Market cap
$4.7B
P/E
0.0×
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Adaptive Biotechnologies Corporation (ADPT) Business Profile

Updated before January 2025

Company Overview

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is a pioneering biotechnology company that specializes in leveraging the adaptive immune system to transform the diagnosis and treatment of diseases. Founded in 2009 by Chad Robins and Harlan Robins, the company is headquartered in Seattle, Washington. Adaptive Biotechnologies has established itself as a leader in immune-driven medicine by combining cutting-edge immunology research with advanced computational biology. The company’s leadership team includes Chad Robins, who serves as CEO, and Harlan Robins, who is the Chief Scientific Officer. Their vision is to harness the power of the immune system to improve patient outcomes and revolutionize healthcare.

Core Business Segments

Adaptive Biotechnologies operates across several core business segments, focusing on immune-driven medicine. These segments include:

1. Immune Medicine Platform

The company’s immune medicine platform is at the heart of its operations. This platform decodes the adaptive immune system by analyzing T-cell and B-cell receptors. Key offerings include:

  • immunoSEQ® Technology: A proprietary sequencing technology that provides insights into the immune system by profiling T-cell and B-cell receptors. It is widely used in research and clinical applications.
  • clonoSEQ® Assay: A diagnostic tool for detecting minimal residual disease (MRD) in blood cancers such as multiple myeloma, chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL). This FDA-cleared assay is a critical tool for monitoring disease progression and treatment response.

2. Drug Discovery and Development

Adaptive Biotechnologies collaborates with pharmaceutical companies to develop novel therapeutics. By leveraging its immune medicine platform, the company identifies and validates drug targets for a range of diseases, including cancer, autoimmune disorders, and infectious diseases.

3. Immune Profiling Services

The company provides immune profiling services to academic institutions, biopharmaceutical companies, and healthcare organizations. These services enable researchers to better understand immune responses and develop targeted therapies.

Business Model

Adaptive Biotechnologies operates a hybrid business model that integrates products, services, and partnerships to generate revenue. The company’s revenue streams include:

  • Product Sales: Revenue from the sale of diagnostic tools like the clonoSEQ® assay.
  • Service Revenue: Income from immune profiling services and licensing of its immunoSEQ® technology.
  • Collaborations and Partnerships: Adaptive Biotechnologies partners with leading pharmaceutical companies, such as Genentech, to co-develop therapeutics. These collaborations often include milestone payments and royalties.

The company’s business model is built on a foundation of innovation, leveraging its immune medicine platform to address unmet medical needs and drive long-term growth.

Strategic Direction

Adaptive Biotechnologies is focused on expanding its product portfolio, enhancing its immune medicine platform, and entering new markets. Key strategic priorities include:

  • Expansion of Diagnostic Applications: The company aims to broaden the use of its clonoSEQ® assay to additional blood cancers and solid tumors.
  • Development of New Therapeutics: By leveraging its immune medicine platform, Adaptive Biotechnologies is working to develop novel immunotherapies for cancer, autoimmune diseases, and infectious diseases.
  • Global Expansion: The company is exploring opportunities to expand its presence in international markets, particularly in Europe and Asia.
  • Sustainability Goals: Adaptive Biotechnologies is committed to sustainability and aims to minimize its environmental footprint through responsible business practices.

Competitive Landscape

Adaptive Biotechnologies operates in a highly competitive biotechnology sector. Key competitors include:

  • Illumina, Inc.: A leader in genomic sequencing technologies.
  • 10x Genomics: Specializes in single-cell sequencing and immune profiling.
  • Foundation Medicine: Focuses on comprehensive genomic profiling for cancer.
  • Guardant Health: Develops liquid biopsy technologies for cancer detection and monitoring.

Despite the competition, Adaptive Biotechnologies differentiates itself through its proprietary immune medicine platform and focus on immune-driven medicine.

Risk Factors

Like any biotechnology company, Adaptive Biotechnologies faces several risks, including:

  • Market Dependence: The company relies heavily on the success of its clonoSEQ® assay and immunoSEQ® technology.
  • Regulatory Challenges: The development and approval of new diagnostics and therapeutics are subject to stringent regulatory requirements.
  • Supply Chain Disruptions: The company’s operations could be impacted by disruptions in the supply chain for critical components and reagents.
  • Competition: Intense competition in the biotechnology sector could impact market share and pricing.

Recent Developments

Adaptive Biotechnologies has made significant strides in recent years. Notable developments include:

  • Launch of T-Detect™ Assay: A diagnostic tool that uses T-cell receptor sequencing to detect diseases such as COVID-19 and Lyme disease.
  • Partnership with Genentech: The collaboration aims to develop personalized cancer immunotherapies.
  • Advancements in MRD Testing: The company continues to enhance its clonoSEQ® assay to improve sensitivity and expand its applications.
  • Response to Global Events: Adaptive Biotechnologies played a critical role during the COVID-19 pandemic by leveraging its immune medicine platform to study immune responses and develop diagnostic tools.

Investment Considerations

Investors considering Adaptive Biotechnologies should weigh the following factors:

Strengths

  • Innovative Technology: Proprietary immune medicine platform with broad applications.
  • Strong Partnerships: Collaborations with leading pharmaceutical companies.
  • Market Leadership: A pioneer in immune-driven medicine with FDA-cleared diagnostics.

Risks

  • High R&D Costs: Significant investment in research and development may impact profitability.
  • Regulatory Risks: Dependence on regulatory approvals for new products.
  • Market Volatility: The biotechnology sector is subject to market fluctuations and investor sentiment.

Conclusion

Adaptive Biotechnologies Corporation is a trailblazer in immune-driven medicine, leveraging its innovative immune medicine platform to transform healthcare. With a strong product portfolio, strategic partnerships, and a commitment to innovation, the company is well-positioned for future growth. However, investors should carefully consider the risks associated with the biotechnology sector. As Adaptive Biotechnologies continues to expand its offerings and enter new markets, it remains a compelling player in the evolving landscape of precision medicine.